[Company Analysis] SK Biopharm. SK Biopharm analysis. SK Biopharm Samsung Biologics Comparison

 

 

Hello everyone, this is diversity from Korea.

 

Finally, the company that everyone was expecting appeared in the Korean Nasdaq, KOSPI. SK Bio pharm. If it were the same as before, I wouldn't have had much hope for it.

 

 

However, as the market was becoming speculative, there were companies that could see that there was no better speculative property.

 

Some believe in and invest in the future of SK Biopharm, and others invest to realize short-term margins. Then, today, we will look at SK Biopharm, a huge prospect that has come to the market with everyone's expectations.

 

 

 

1. Basic information of SK Biopharm

---

SK Biopharm was established in 2011. It was a coincidence or was established on April 1st, April Fools' Day. The listing date is July 2, 2020.

 

Since the listing, it has been monopolizing the market's interest to the extent that it has attracted tremendous interest in subscription to SK Biopharm, and has also influenced nearby companies to create the word SK Biopharm related stock.

 

 

 

The market cap was recorded to reach 13 trillion won by July 3, but the market cap is expected to continue to increase due to the large number of pending purchases.

 

 

Mainly engaged in the development of new drugs in the field of epilepsy, it has a diverse pipeline and has a pipeline that has already reached Phase 3 and is showing a good appearance as a bio company.

 

As of the end of 2019, sales are recorded at 120 billion won, and the number of employees is known to be 200.

 

 

 

2. Outlook of SK Biopharm's share price

---

SK Biopharm is an item that emerged in the great interest of the market. SK Biopharm's employees have been interested in every aspect to the extent of how much profit they have made, and stock prices are rising accordingly.

 

 

SK Biopharm's share price is expected to continue to rise in the near future. There are many things that aren't related to the value or performance of a company, so there are many stories that the funds introduced since Corona19 have turned the market into speculation.

 

 

Many people are aiming to realize short-term margins, and this is a highly liquid market. In fact, Samsung Heavy Industries' preferred stock quickly rose from 40,000 won to 900,000 won.

 

No one bought the stock for hundreds of thousands of won considering the future value of Samsung Heavy Industries.

 

 

Personally, I think Samsung Heavy Industries' preferred stock will never reach 900,000 won again. It is the money that has been moved to realize the short-term margins, and it is the best part of the market.

 

SK Biopharm has appeared in this market. Stock prices can continue to rise. It can go up without knowing where the end is.

 

However, this would involve a large number of speculative trades, and it is expected that a plunge will be possible as well.

 

 

 

3. What to expect from SK Biopharm 1 - SK Group affiliates

---

It is true that it is a speculative market. However, SK Biopharm has other expectations. First, SK Biopharm is an affiliate of SK Group.

 

Many are looking forward to the success of new drugs and future growth because they are a company with tremendous support from large companies.

 

 

Many companies developing new drugs are mid-sized and small and medium-sized businesses. They are struggling with a difficult time and have a hard time. SK Biopharm is a company that can fully support SK Group.

 

As system performance and investment are in place, we are creating better outcomes, and we are rising to the expectation that we will show good results in the new drug market in the future.

 

 

 

4. Reasons to expect SK Biopharm 2-Samsung Biologics

---

The share price of Samsung Biologics has grown tremendously. There are stories about politics and tax evasion, but they showed how to act as a captain among bio companies.

 

 

Some people believe that SK Biopharm will grow into a company that will fight Samsung Biologics. That's why we are investing in SK Biopharm.

 

In reality, it is a little different. Unlike other bio companies, Samsung Biologics has few good appearances in the field of new drug development, and is showing good appearance in biopharmaceutical consignment production

 

 

Most new drug development companies are medium-sized and small and medium-sized companies, so they work hard, but they have difficulties in the final stages of production or production.

 

Samsung Biologics is a company that provides biopharmaceutical consignment production services to them. SK Biopharm, unlike Samsung Biologics, develops new drugs.

 

 

We have a variety of brain disease related pipelines, and if research is successfully completed, we will enter the trillion won market.

 

Since they are affiliated with Samsung Group and SK Group, they often see them similarly. However, the two companies are on a slightly different path and are expected to look different in the future.

 

 

I am curious how SK Biopharm's stock price will move in the future. It's a company that's wondering where to go, and I'm not going to buy it, but it's a company that I'll keep watching.

 

I will finish posting with the above. Have a healthy day!!